COMMUNIQUÉS West-GlobeNewswire

Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
12/08/2024
BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the [...]
Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
12/08/2024
Phase 2b ASCEND trial top-line data remains on track to be reported in fourth quarter of 2024 Available cash projected to fund current operations into early 2026 and all active studies through to data Conference call [...]
Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
12/08/2024
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 - - ODYSSEY Safety Review Committee Recommends Trial Continue as Planned with no Serious Adverse Events Observed - - Recent [...]
Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights
12/08/2024
- 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable [...]
Firefly Neuroscience Announces Closing of Merger Agreement and is Scheduled to Begin Trading on Nasdaq Under the Ticker Symbol ‘AIFF’ on August 13, 2024
12/08/2024
In connection with the consummation of the merger, the Company closed $3.5 million private placement offering FAIRFAX, Va. and TORONTO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “ [...]
Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX
12/08/2024
Latest innovation in Robotic Magnetic Navigation technology supports broad accessibility of robotics for minimally-invasive endovascular surgery GenesisX has obtained CE mark in Europe and has been submitted to the FDA [...]
Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
12/08/2024
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million [...]
Erasca Reports Second Quarter 2024 Business Updates and Financial Results
12/08/2024
In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors Initiated SEACRAFT-2 [...]
Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
12/08/2024
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy [...]
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results
12/08/2024
BBI-355 POTENTIATE clinical trial ongoing with initiatives implemented to expedite enrollment in combination cohorts; initial proof-of-concept data now expected in the second half of 2025 BBI-825 STARMAP clinical trial [...]
Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights
12/08/2024
WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a [...]
Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024
12/08/2024
SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024. “We [...]
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21
12/08/2024
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 Company to Host Conference Call with Live Q&A, August 21, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and [...]
Eric Samples Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager
12/08/2024
MINNEAPOLIS, MN, US, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical [...]
NeuroOne® to Report Third Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on August 14
12/08/2024
EDEN PRAIRIE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and [...]
Milestone Scientific Schedules Second Quarter 2024 Financial Results and Business Update Conference Call
12/08/2024
ROSELAND, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that [...]
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
12/08/2024
Press Release – No. 8 / 2024 Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results Copenhagen, Denmark, August 12, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: [...]
scPharmaceuticals Announces Pricing of $50.0 Million Public Offering
12/08/2024
BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of [...]
Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma
12/08/2024
SHANGHAI, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]

Pages